Amneal Pharmaceuticals, Inc. - Class A Common Stock — Filings & Documents (NASDAQ:AMRX) — Page 11 | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

2018

Current report, Q2 FY2018

Amneal Pharmaceuticals, Inc. current report, Q2 FY2018

Current report, Q2 FY2018

Amneal Pharmaceuticals, Inc. current report, Q2 FY2018

1
...
4
5
6
7
8
9
10
11

News

AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study

BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program

JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer

SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis

RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy

Here's Why You Should Add ACET Stock to Your Portfolio Now

Acadia Gets European Commission Nod for Daybu in Rett Syndrome

Are Medical Stocks Lagging Bioventus (BVS) This Year?

Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?

TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette Syndrome

Reasons Why Investors Should Consider Betting on PGEN Stock

RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos